Download Full Text (932 KB)


Global Health Conference Midwest

Document Type


Publication Date


Abstract or Description

Radiation therapy is a common treatment modality offered to patients with localized prostate cancer. It can be associated with early radiation-induced toxicities including dysuria, nocturia, frequency, urgency, spasm, and rarely hematuria. Early toxicities usually resolve once the treatment period has ended. Chronic toxicities are less common, and rarely, patients may experience radiation-induced hemorrhagic cystitis and hematuria months to years after radiation. We herein describe the case of a 65-year-old male with a past medical history of type 2 diabetes mellitus who experienced hemorrhagic cystitis for months following his radiation therapy. The patient was on Sodium-Glucose Cotransporter-2 inhibitor therapy (Jardiance), which we highlight as a potential risk factor for hemorrhagic cystitis. After cessation of Jardiance and initiation of Ozempic (GLP-1 agonist), his urinary symptoms significantly improved. To the best of our knowledge, this is the first such case reported.

SGLT2i Use Potentiates Acute and Chronic Radiation-Induced Side Effects in Prostate Cancer Radiation Therapy